Literature DB >> 22155414

Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid.

Varaporn Buraphacheep Junyaprasert1, Pratyawadee Singhsa, Jiraphong Suksiriworapong, Doungdaw Chantasart.   

Abstract

Ellagic acid (EA) is a potent antioxidant phytochemical substance which has limitation to use due to its poor biopharmaceutical properties, low solubility and low permeability. The aim of the present study was to develop niosomal formulations obtained from the mixture of Span 60 and Tween 60 that could encapsulate EA for dermal delivery. The EA-loaded niosomes were prepared with 1:0, 2:1, 1:1, 0:1 Span 60 and Tween 60, using polyethylene glycol 400 (PEG 400), propylene glycol (PG) or methanol (MeOH) as a solubilizer. The influence of formulations on vesicle size, entrapment efficiency and stability of EA-loaded niosomes was investigated. It was found that all ratios of surfactants could produce EA-loaded niosomes when using 15% (v/v) PG, 15% (v/v) PEG 400 or 20% (v/v) MeOH. The niosomes were spherical multilamellar vesicles showing the localization of EA in the vesicles. The vesicle sizes of the niosomes after extrusion were 124-752 nm with PI less than 0.4. The percentages of entrapment efficiency (% E.E.) of all EA-loaded niosomes varied between 1.35% and 26.75% while PEG 400 niosomes gave the highest % E.E. The most stable and highest entrapped formulation was 2:1 Span 60 and Tween 60 niosomes. Additionally, the in vitro skin permeation revealed that penetration of EA from the niosomes depended on vesicle size, the amount of EA entrapped and the added solubilizers which could act as a permeation enhancer. From skin distribution study, the EA-loaded niosomes showed more efficiency in the delivery of EA through human epidermis and dermis than EA solution. The results indicated that the Span 60 and Tween 60 niosomes may be a potential carrier for dermal delivery of EA.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155414     DOI: 10.1016/j.ijpharm.2011.11.032

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  20 in total

Review 1.  Human skin models: From healthy to disease-mimetic systems; characteristics and applications.

Authors:  Tânia Moniz; Sofia A Costa Lima; Salette Reis
Journal:  Br J Pharmacol       Date:  2020-08-19       Impact factor: 8.739

Review 2.  Use of Polyphenolic Compounds in Dermatologic Oncology.

Authors:  Adilson Costa; Michael Yi Bonner; Jack L Arbiser
Journal:  Am J Clin Dermatol       Date:  2016-08       Impact factor: 7.403

3.  Preparation and In Vivo Evaluation of Rosmarinic Acid-Loaded Transethosomes After Percutaneous Application on a Psoriasis Animal Model.

Authors:  Virginia Motilva; María Luisa González-Rodríguez; Azahara Rodríguez-Luna; Elena Talero; Javier Ávila-Román; Ana María Fernández Romero; Antonio M Rabasco
Journal:  AAPS PharmSciTech       Date:  2021-03-12       Impact factor: 3.246

4.  Potentiality of Melittin-Loaded Niosomal Vesicles Against Vancomycin-Intermediate Staphylococcus aureus and Staphylococcal Skin Infection.

Authors:  Sirikwan Sangboonruang; Natthawat Semakul; Mohammad A Obeid; Marta Ruano; Kuntida Kitidee; Usanee Anukool; Kidsadagon Pringproa; Panuwan Chantawannakul; Valerie A Ferro; Yingmanee Tragoolpua; Khajornsak Tragoolpua
Journal:  Int J Nanomedicine       Date:  2021-11-16

5.  Sorbitan Monolaurate-Containing Liposomes Enhance Skin Cancer Cell Cytotoxicity and in Association with Microneedling Increase the Skin Penetration of 5-Fluorouracil.

Authors:  Luiziana Cavalcante Costa Fernandes Crisóstomo; Genuína Stephanie Guimarães Carvalho; Luzia Kalyne Almeida Moreira Leal; Tamara Gonçalves de Araújo; Karina Alexandre Barros Nogueira; Durcilene Alves da Silva; Fábio de Oliveira Silva Ribeiro; Raquel Petrilli; Josimar O Eloy
Journal:  AAPS PharmSciTech       Date:  2022-08-02       Impact factor: 4.026

6.  Vancomycin-eluting niosomes: a new approach to the inhibition of staphylococcal biofilm on abiotic surfaces.

Authors:  Heba S Barakat; Mervat A Kassem; Labiba K El-Khordagui; Nawal M Khalafallah
Journal:  AAPS PharmSciTech       Date:  2014-06-04       Impact factor: 3.246

7.  Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37.

Authors:  Somayeh Sadeghi; Haleh Bakhshandeh; Reza Ahangari Cohan; Afshin Peirovi; Parastoo Ehsani; Dariush Norouzian
Journal:  Int J Nanomedicine       Date:  2019-12-10

8.  In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration.

Authors:  H O Ammar; M Haider; M Ibrahim; N M El Hoffy
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

9.  Enhanced uptake and transport of (+)-catechin and (-)-epigallocatechin gallate in niosomal formulation by human intestinal Caco-2 cells.

Authors:  Qinxin Song; Danhui Li; Yongzhi Zhou; Jie Yang; Wanqi Yang; Guohua Zhou; Jingyuan Wen
Journal:  Int J Nanomedicine       Date:  2014-05-08

Review 10.  Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson's disease models.

Authors:  Palanivel Ganesan; Hyun-Myung Ko; In-Su Kim; Dong-Kug Choi
Journal:  Int J Nanomedicine       Date:  2015-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.